Fluticasone furoate for the treatment of childhood asthma

References

• World Health Organization. Asthma fact sheet N307. Updated November 2003. Available from: www.who.int/mediacentre/factsheets/fs307/en/ [Last accessed 16 April 2015]
   Google Scholar
• Moorman JE, Akinbami LJ, Bailey CM, et al. National surveillance of asthma: United States, 2001–2010. National Center for Health Statistics. Vital Health Stat 2012;3:35
   Google Scholar
• National asthma education and prevention program national heart, lung, and blood institute. Expert panel report 3: Guidelines for the diagnosis and management of asthma. US Department of Health and Human Services; 2007. Available from: www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines [Last accessed 13 July 2015]
   Google Scholar
• From the global strategy for asthma management and prevention, global initiative for asthma (GINA) 2015. Available from: www.ginasthma.org/ [Last accessed 16 April 2015]
   Google Scholar
• Bender BG, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 2004;4:191-5
   PubMed Web of Science ®Google Scholar
• Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am 2005;25(1):107-30
   PubMed Web of Science ®Google Scholar
• Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012;18(7):527-39
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700
   PubMed Web of Science ®Google Scholar
• Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293(3):L660-7
   PubMed Web of Science ®Google Scholar
• Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol 2011;670(1):244-51
   PubMed Web of Science ®Google Scholar
• Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet 2013;52(1):37-42
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8 week, randomised, placebo-controlled trial. Thorax 2012;67(1):35-41
   PubMed Web of Science ®Google Scholar
• Arnuity Elitpa Product Insert. Available from: www.arnuity.com [Last accessed 16 May 15]
   Google Scholar
• Oliver A, Allen A, VanBuren S, et al. Qaqundah. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate, a novel inhaled corticosteroid in children aged 5–11 years with persistent asthma: a randomized trial. Clin Pharmacol Drug Devel 2013;3(2):144-50
   Google Scholar
• Ahmet A, Kim H, Spier S. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin Immunol 2011;7:13
   Google Scholar
• Dresser GK, Spence JD, Bailey DG. Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Data on File. HZA102942 (YM2010/00094/00).
   Google Scholar
• Oliver A, VanBuren S, Allen A, et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5–11 years with persistent asthma. Clin Ther 2014;36(6):928-39
   PubMed Web of Science ®Google Scholar
• Busse WW, O’Byrne PM, Bleecker ER, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial. Thorax 2013;68(6):513-20
   PubMed Web of Science ®Google Scholar
• Lee LA, Sterling R, Mapero J, et al. Growth velocity reduced with once-daily fluticasone furoate nasal spray in prepubescent children with perennial allergic rhinitis. J Allergy Clin Immunol Pract 2014;2:421-7
   PubMed Web of Science ®Google Scholar
• The Childhood Asthma Management Program Research Group. The childhood asthma management program research group. long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343:1054-63
   PubMed Web of Science ®Google Scholar
• Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012;367:904-12
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343:1064-9
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Data on File. HZA112777 (2011N127524_00)
   Google Scholar
• Meltzer EO, Lee J, Tripathy I, et al. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk. Pediatr Allergy Immunol 2009;20:279-86
   PubMed Web of Science ®Google Scholar
• van den Berge M, Luijk B, Bareille P, et al. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy 2010;65(12):1531-5
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bateman ED, Busse WW, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res 2011;12:132
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res 2011;12:160
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bleecker ER, Lötvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med 2012;106(5):642-50
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bleecker ER, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24 week placebo and active-controlled randomised trial. Respir Med 2014;108(1):41-9
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Woodcock A, Bleecker ER, et al. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Respir Res 2014;15:88
   PubMed Web of Science ®Google Scholar
• Medley H, Orozco S, Allen A. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Clin Ther 2012;34(8):1683-95
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Bateman ED, Busse WW, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol 2012;109(5):353-358.e4
   PubMed Web of Science ®Google Scholar
• Busse WW, Bateman ED, O’Byrne PM, et al. Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. Allergy 2014;69(11):1522-30
   PubMed Web of Science ®Google Scholar
• Woodcock A, Lötvall J, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. BMC Pulm Med 2014;14:113
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Lötvall J, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest 2013;144(4):1222-9
   PubMed Web of Science ®Google Scholar
• Lin J, Kang J, Lee SH, et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respir Med 2015;109(1):44-53
   PubMed Web of Science ®Google Scholar
• Bateman ED, O’Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax 2014;69(4):312-19
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J 2014;43(3):773-82
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Lötvall J, O’Byrne PM, et al. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract 2014;2(5):553-61
   PubMed Web of Science ®Google Scholar
• British thoracic society. British guideline on the management of asthma. 2008. (revised June 2009). Available from: www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Asthma/Guidelines/sign101%20revised%20June%2009.pdf
   Google Scholar
• Burgess S, Sly P, Devadason S. Adherence with preventive medication in childhood asthma. Pulm Med 2011 2011
   Google Scholar
• Rhee H, Belyea MJ, Halterman JS. Adolescents’ Perception of Asthma Symptoms and Health Service Utilization. J Pediatr Health Care 2011;25:105-13
   PubMedGoogle Scholar
• Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. New Eng J Med 2006;354:1985-97
   PubMed Web of Science ®Google Scholar
• Grzela K, Zagorska W, Krejner A, et al. Prolonged treatment with inhaled corticosteroids does not normalize high activity of matrix metalloproteinase-9 in exhaled breath condensates of children with asthma. Arch Immunol Ther Exp 2015;63:231-7
   Google Scholar
• Kwok PCL, Chan H-K. Delivery of inhalation drugs to children for asthma and other respiratory disease. Adv Drug Del Rev 2014;73:83-8
   PubMed Web of Science ®Google Scholar
• Fink JB. Delivery of inhaled drugs for infants and small children: a commentary on present and future needs. Clin Therapeut 2012;34:S36-45
   PubMed Web of Science ®Google Scholar
• Champaloux SW, Young DR. Childhood chronic health conditions and educational attainment: a social ecological approach. J Adol Health 2015;56:98-105
   PubMed Web of Science ®Google Scholar
• Maykut R, Zeiger RS, Brown MA. Asthma in pediatric patients: unmet needs and therapeutic options. Clin Pediatr 2010;49:915-30
   Google Scholar
• Oliver A, Quinn D, Goldfrad C, et al. Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial. Clin. Transl. Allergy 2012;2(1):11
   Google Scholar
• Kempsford RD, Oliver A, Bal J, et al. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respir. Med 2013;107(12):1873-80
   PubMed Web of Science ®Google Scholar